APN 401Alternative Names: APN401; siRNA-transfected peripheral blood mononuclear cells - Apeiron
Latest Information Update: 07 Oct 2016
At a glance
- Originator Apeiron Biologics
- Developer Apeiron Biologics; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (USA)
- Class Antineoplastics; Cell therapies; Gene therapies; Small interfering RNA; Small molecules
- Mechanism of Action CBLB protein expression inhibitors; RNA interference; Ubiquitin-protein ligase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours